IRIS
GOZZETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.642
EU - Europa 11.334
AS - Asia 6.293
SA - Sud America 1.504
AF - Africa 126
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 11
Totale 34.921
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.469
RU - Federazione Russa 2.657
GB - Regno Unito 2.294
CN - Cina 2.265
SG - Singapore 2.028
IE - Irlanda 1.689
BR - Brasile 1.278
IT - Italia 1.248
UA - Ucraina 855
SE - Svezia 806
FR - Francia 566
HK - Hong Kong 552
DE - Germania 545
VN - Vietnam 460
KR - Corea 340
FI - Finlandia 300
IN - India 148
CA - Canada 98
TR - Turchia 88
AR - Argentina 78
BD - Bangladesh 73
NL - Olanda 68
PL - Polonia 56
JP - Giappone 51
ID - Indonesia 45
IQ - Iraq 45
MX - Messico 45
ZA - Sudafrica 44
EC - Ecuador 39
AT - Austria 38
ES - Italia 36
BE - Belgio 35
MA - Marocco 29
CZ - Repubblica Ceca 26
VE - Venezuela 23
CO - Colombia 22
PY - Paraguay 22
UZ - Uzbekistan 21
LT - Lituania 20
SA - Arabia Saudita 20
IR - Iran 19
CL - Cile 18
PK - Pakistan 15
KZ - Kazakistan 14
RS - Serbia 14
PE - Perù 13
CH - Svizzera 12
CI - Costa d'Avorio 12
JO - Giordania 12
AU - Australia 11
EG - Egitto 11
AZ - Azerbaigian 9
TW - Taiwan 9
DO - Repubblica Dominicana 8
LB - Libano 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
EE - Estonia 7
EU - Europa 7
IL - Israele 7
TN - Tunisia 7
BO - Bolivia 6
DZ - Algeria 6
NP - Nepal 6
PT - Portogallo 6
RO - Romania 6
TH - Thailandia 6
TT - Trinidad e Tobago 6
AO - Angola 5
DK - Danimarca 5
KE - Kenya 5
KG - Kirghizistan 5
OM - Oman 5
PH - Filippine 5
PS - Palestinian Territory 5
SK - Slovacchia (Repubblica Slovacca) 5
BG - Bulgaria 4
LK - Sri Lanka 4
LU - Lussemburgo 4
LV - Lettonia 4
PA - Panama 4
UY - Uruguay 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
GR - Grecia 3
LA - Repubblica Popolare Democratica del Laos 3
NG - Nigeria 3
NI - Nicaragua 3
BH - Bahrain 2
CR - Costa Rica 2
CW - ???statistics.table.value.countryCode.CW??? 2
ET - Etiopia 2
GT - Guatemala 2
HR - Croazia 2
JM - Giamaica 2
KW - Kuwait 2
MK - Macedonia 2
NO - Norvegia 2
SM - San Marino 2
Totale 34.903
Salva come PNG Salva come JPEG
Città #
Fairfield 2.035
Southend 1.986
Dallas 1.941
Dublin 1.666
Ashburn 1.162
Singapore 1.130
Woodbridge 989
Chandler 813
Seattle 786
Houston 783
Wilmington 768
Moscow 742
Jacksonville 733
Santa Clara 684
Cambridge 638
Beijing 603
Hong Kong 549
Ann Arbor 409
Princeton 372
Hefei 354
Seoul 339
Siena 325
Nanjing 248
Los Angeles 196
Ho Chi Minh City 145
Munich 138
San Mateo 133
The Dalles 129
São Paulo 120
Helsinki 116
Boardman 111
Milan 107
New York 106
Buffalo 105
San Diego 102
Florence 93
Dong Ket 88
Nanchang 77
Shanghai 75
Hanoi 74
Rome 70
London 67
Dearborn 63
Redondo Beach 57
Shenyang 56
Menlo Park 50
Turku 50
Bengaluru 49
Hebei 48
Izmir 47
San Francisco 46
Columbus 45
Tianjin 44
Warsaw 43
Tokyo 42
Nuremberg 41
Lappeenranta 40
Council Bluffs 39
Jiaxing 38
Kunming 36
Stockholm 35
Brussels 34
Denver 33
Phoenix 32
Rio de Janeiro 31
Chicago 30
Toronto 30
Brooklyn 29
Montreal 28
Atlanta 27
Changsha 27
Zhengzhou 26
Dhaka 25
Norwalk 25
Curitiba 24
Johannesburg 24
Belo Horizonte 23
Brasília 23
Porto Alegre 23
Frankfurt am Main 22
Turin 21
Chennai 20
Guangzhou 20
Kilburn 20
Mexico City 20
Portsmouth 20
Baghdad 19
Bologna 19
Lauterbourg 19
Orem 19
Poplar 19
Tashkent 19
Vienna 19
Jinan 18
Salvador 18
Brno 17
Düsseldorf 17
Ningbo 17
Da Nang 16
Guarulhos 16
Totale 23.865
Salva come PNG Salva come JPEG
Nome #
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients 302
Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. 300
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 295
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 284
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 281
Preferential usage of specific immunoglobulin heavy chain variable region genes with unmutated profile and advanced stage at presentation are common features in patients with chronic lymphocytic leukemia from Senegal 279
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 273
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 270
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 269
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 269
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 267
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 264
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 262
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 257
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 257
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 252
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 248
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 245
Second generation proteasome inhibitors in multiple myeloma 243
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 235
Central nervous system multiple myeloma 233
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 233
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) 231
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 230
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 226
Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis 224
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 223
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 222
EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma. 221
Adult lymphoblastic lymphoma: Clinical features and prognostic factors in 53 patients 219
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 217
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 215
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 215
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 208
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 207
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 207
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 205
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 203
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 202
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 199
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 197
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 195
FLT3 inhibitors in the management of acute myeloid leukemia 195
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 194
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors 194
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 194
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients 193
Daratumumab efficacy in extramedullary orbital myeloma 193
Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy 189
A novel t(6;7)(p24;q21) in a chronic myelocytic leuckemia in complete cytogenetic remission after therapy with imatinib mesylate 189
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 189
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 188
Treatment of smoldering multiple myeloma 187
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 186
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 186
Evolving treatments in multiple myeloma patients with renal failure 185
Hyperlipidemia in a myeloma patient after bortezomib treatment 185
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 185
Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports 184
Predicting the clinical course of Hodgkin lymphoma 183
Extramedullary myeloma relapses 183
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 183
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 182
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 180
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 180
An unusual presentation of chronic B-cell lymphocytic leukaemia 178
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 177
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 176
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol 175
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature 174
Bcr-abl peptides for chronic myeloid leukemia. 174
The effects of zoledronic acid on serum lipids in multiple myeloma patients 174
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 172
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma 170
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice 167
Unusual localizations of plasmacytoma 166
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 165
Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission 165
Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region 165
Reply to “Rituximab activity in CD20-positive multiple myeloma” 164
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma 164
Central Nervous System Multiple Myeloma 162
Anti CD38 monoclonal antibodies for multiple myeloma treatment 162
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: A phase II study 161
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study 161
Intracranial involvement in plasmacytomas and multiple myeloma: A pictorial essay 159
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 159
Central nervous system multiple myeloma: a different cytogenetic profile 158
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 158
Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia 157
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 156
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide- dexamethasone incorporated into double autologous transplantation 154
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia 154
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 153
Cost of illness in patients with multiple myeloma in Italy: The CoMiM study 153
Evidences of new risk factors for retinal vein thrombosis 153
Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy 152
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 152
Insights into JAK2-V617F mutation in CML. 151
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up 151
Totale 20.083
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.534
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.534
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.307 0 0 0 0 0 427 139 547 279 375 257 283
2021/20222.442 160 250 174 179 93 100 125 91 126 285 276 583
2022/20233.273 240 227 440 475 281 677 87 248 298 46 188 66
2023/20242.461 105 57 226 133 68 612 849 48 20 69 39 235
2024/20255.875 173 295 556 321 650 375 158 333 480 347 644 1.543
2025/20269.161 1.072 2.039 1.555 1.873 2.445 177 0 0 0 0 0 0
Totale 35.477